[Advances in the Treatment of Acute Myeloid Leukemia with TP53 Mutations-Review]
{{output}}
Acute myeloid leukemia (AML) is the most common hematological malignancies in adults. TP53, as a tumor suppressor gene, has a mutation rate of about 5%-10% in AML patients. In 2017, the European Leukemia Net first classified AML with TP53 mutations as an unfav... ...
